While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

At Tata Consumer Products, Das drives growth strategy, outcomes and profit & loss for the packaged beverages category in ...

Our writer Ken Hall evaluates two defensive dividend payers in the FTSE 100 that he thinks investors should consider buying ...

Pfizer has officially kissed goodbye to its consumer health venture by selling its final 7.3% stake in Haleon for a tidy $3.3 ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. | After charting similar moves ...

Bengaluru: Pfizer will divest its remaining stake in Haleon, marking its complete exit from the British consumer healthcare ...

Pfizer still owns about 7.3% of the company making it the largest shareholder. GSK sold its remaining stake in May last year.